ArticleBlood2022

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.

Peter Martin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.